2020 Year in Review - Ovarian Cancer
2020 Year in Review - Ovarian Cancer | January 20, 2021
Personalized starting doses of niraparib based on body weight and platelet count are associated with reductions in thrombocytopenia and other hematologic events.
2020 Year in Review - Ovarian Cancer | January 20, 2021
When utilized as maintenance therapy after frontline treatment of ovarian cancer in patients with BRCAwt tumors, niraparib improved progression-free survival (PFS), even in the most difficult-to-treat patients.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Results from a previous study indicated that treatment with the combination would lead to improvement in progression-free survival (PFS) compared with treatment with olaparib alone.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Treatment with rucaparib was associated with improvements in progression-free survival, time to first subsequent treatment, and other post-progression efficacy end points.
2020 Year in Review - Ovarian Cancer | January 20, 2021
In this study, researchers explored whether there is a potential synergistic effect of olaparib when combined with pegylated liposomal doxorubicin, highlighting a potential means to improve tolerability.
2020 Year in Review - Ovarian Cancer | January 20, 2021
The phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 study is exploring the use of an antimitotic therapy tumor treating (TT) fields plus weekly paclitaxel in patients with platinum-resistant ovarian cancer.
2020 Year in Review - Ovarian Cancer | January 20, 2021
The combination of lenvatinib + pembrolizumab exhibited a manageable safety profile and encouraging efficacy in patients with heavily pretreated ovarian cancer, as well as those with a previous history of treatment failure.
2020 Year in Review - Ovarian Cancer | January 20, 2021
In the phase 2 OVARIO study, median progression-free survival (PFS) has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Are patient-reported outcomes (PROs) similar in the placebo and the niraparib groups, suggesting that over the course of treatment niraparib does not adversely affect patients’ quality of life? Results of the PRIMA/ENGOT-OV26/GOG-3012 trial begin to elucidate the answer to this question.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Although researchers noted a trend toward increased incidence of secondary hematologic malignancy in patients with newly diagnosed ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors, the difference was not statistically significant.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Combination treatment is even more effective in women with ovarian cancer with BRCA mutations or homologous recombination deficiency (HRD)-positive tumors.
2020 Year in Review - Ovarian Cancer | January 20, 2021
In patients with newly diagnosed, advanced ovarian cancer and BRCA mutation, olaparib demonstrated a consistently high reduction in the risk for cancer progression and death.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Robotic interval debulking surgery is efficient and safe when treating patients with advanced ovarian cancer who are receiving neoadjuvant chemotherapy.
2020 Year in Review - Ovarian Cancer | January 20, 2021
NOVA clinical trial data outcomes were superior to the real-world outcomes for niraparib, highlighting the critical need for better understanding of variables impacting poly (ADP-ribose) polymerase (PARP) inhibitor outcomes in clinical practice.
2020 Year in Review - Ovarian Cancer | January 20, 2021
The RESPONSE study will help characterize patient characteristics and regional specific therapeutic management strategies adopted in 7 countries to better understand poly (ADP-ribose) polymerase (PARP) inhibitor use and its impact on outcomes.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Researchers evaluated the connections between safety and efficacy and rucaparib pharmacokinetic exposure in patients with recurrent ovarian cancer.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Treatment with niraparib improves progression-free survival (PFS) in patients with ovarian cancer regardless of their biomarker status.
2020 Year in Review - Ovarian Cancer | January 20, 2021
An analysis of phase 3 data from ARIEL3 was reviewed, providing insight into treatment-emergent adverse events (AEs) in patients receiving maintenance therapy with rucaparib for ovarian cancer.
2020 Year in Review - Ovarian Cancer | January 20, 2021
An investigation of whether adding a maintenance therapy regimen of olaparib combined with bevacizumab provided a benefit beyond first progression in patients with newly diagnosed advanced high‐grade ovarian carcinoma.
2020 Year in Review - Ovarian Cancer | January 20, 2021
A recent study explores niraparib’s efficacy, safety, and effect on quality of life in compared age-groups.
2020 Year in Review - Ovarian Cancer | January 20, 2021
In patients with high-grade ovarian cancer harboring BRCA mutations and a confirmed response to rucaparib, BRCA homozygous deletion or rearrangement was associated with a significantly longer duration of response.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Despite substantial rates of intraoperative tumor spillages, patients with ovarian germ cell tumors (OGCTs) had an excellent prognosis, and adjuvant chemotherapy showed evidence of preventing disease recurrence.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Is subsequent chemotherapy less effective for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer who have been treated with olaparib as maintenance therapy? Here we discuss the latest findings from the SOLO2/ENGOT Ov-21 clinical trial.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Due to a variety of factors, first-line therapy with atezolizumab failed to demonstrate significant activity in patients with newly diagnosed stage III or stage IV ovarian cancer.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Olaparib maintenance monotherapy not only delays disease progression but also improves overall survival (OS) in women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation.
2020 Year in Review - Ovarian Cancer | January 20, 2021
This real-world study based primarily on community-based practice data showed that a key predictor of time to next treatment and mortality in patients with advanced ovarian cancer was visible residual disease.
Results 1 - 27 of 27
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512